Evidence map›Paper›PMID 40248950›Full record

ArticleFuture oncology (London, England)2025

STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC.

Nabil F Saba, Kevin Harrington, Lisa Licitra, Jean-Pascal Machiels, Cixin He, Taylor Jew, Vasily Andrianov, Robert Haddad

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06082167 (A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06082167 phase2 / phase3active not recruitingnot on this map

A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

TypeinterventionalSponsorExelixisRan2024 to 2029Enrolled600ConditionsHead and Neck Squamous Cell CarcinomaArmsZanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nabil F SabaDepartment of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA.ORCID 0000-0003-4972-1477
Kevin HarringtonDivision of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.ORCID 0000-0002-6014-348X
Lisa LicitraHead and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0000-0003-0623-4118
Jean-Pascal MachielsInstitut de Recherche Expérimentale et Clinique, Pôle MIRO, Université catholique de Louvain, Brussels, Belgium.ORCID 0000-0001-6369-9742
Cixin HeExelixis, Inc, Alameda, CA, USA.
Taylor JewExelixis, Inc, Alameda, CA, USA.
Vasily AndrianovExelixis, Inc, Alameda, CA, USA.ORCID 0009-0005-1895-9126
Robert HaddadDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-1413-0079

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

tweetable abstractSTELLAR-305: design of an ongoing phase III #clinicaltrial, assessing the multi-targeted tyrosine kinase inhibitor, zanzalintinib, in combination with pembrolizumab in previously untreated recurrent/metastatic #HNSCC. CLINICAL

trial registrationNCT06082167 (ClinicalTrials.gov).

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicFemaleHumansMaleMiddle AgedMulticenter Studies as TopicProtein Kinase InhibitorsRandomized Controlled Trials as TopicTreatment OutcomeAntibodies, Monoclonal, HumanizedpembrolizumabProtein Kinase InhibitorsHead and neck squamous cell carcinomaHNSCCimmune checkpoint inhibitorpembrolizumabphase II/IIItyrosine kinase inhibitorXL092zanzalintinib

Identifiers

PMID40248950
PMCPMC12057161

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.